|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Xenografts of NaAsIII‑preconditioned MCF7 cells (MCF7NaAsIII) into the mammary fat pads of nude mice produced a larger tumor volume compared to tumors from control MCF7 cells and were more refractory to TAM in association with the reduced expression of BRCA1 and ERα, CpG hypermethylation of estrogen receptor 1 (ESR1) and BRCA1, and the increased expression of FOLR1.
|
30664189 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
|
31679978 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The correlation between <sup>89</sup>Zr-M9346A tumor uptake and treatment response using IMGN853 in FRα<sup>high</sup> TNBC PDX model suggested the potential of <sup>89</sup>Zr-M9346A PET as a noninvasive tool to prescreen patients based on the in vivo PET imaging for IMGN853-targeted treatment.
|
31369274 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have demonstrated the effectiveness of FA conjugated QDs to target tumor spheroids thus confirming the crucial role of FRα receptor as a target.
|
30885845 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FOLR1 targeting resulted in disassembly of the porphysomes and subsequent fluorescence activation in intrathoracic disseminated MPM tumors, as demonstrated by ex vivo tissue imaging.
|
30226590 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pituitary adenomas are known to overexpress folate receptor alpha (FRα), and it was hypothesized that OTL38, a folate analog conjugated to a near-infrared (NIR) fluorescent dye, could provide real-time intraoperative visual contrast of the tumor versus the surrounding nonneoplastic tissues.
|
28841122 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.
|
29129656 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, MOv18-IgG1 triggered immune-dependent cancer cell death <i>in vitro</i> by human volunteer and breast cancer patient immune cells, and significantly restricted orthotopic and patient-derived xenograft growth.<b>Conclusions:</b> FRα is overexpressed in high-grade TNBC and postchemotherapy residual tumors.
|
30068707 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This highly tumor restricted expression profile makes FRα a promising target for tumor therapy and diagnosis.
|
29849110 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report that CART cells targeting the folate receptor alpha (FR-α) successfully infiltrated preestablished xenograft tumors but failed to induce complete responses, presumably due to the presence of antigen-negative cancer cells.
|
29588319 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DATA CONCLUSION: <sup>19</sup> F MRI with FR-targeted PFC nanoparticles can be used in differentiating of FR-positive and FR-negative tumors, and further, in evaluation of the two cancer models proliferation.
|
29756310 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eligibility included a minimum requirement of tumor FRα positivity (≥25% of cells with ≥2+ staining intensity).
|
30093227 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In our previous study, we demonstrated that folate-appended methyl‑β‑cyclodextrin (FA-M-β-CyD) was a promising antitumor agent for the treatment of folate receptor-α (FR-α)-expressing tumors.
|
29486262 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853, shows great antitumor activity against FRα-expressing tumors in vivo, but patient selection and consequently therapy outcome are based on immunohistochemistry.
|
30155674 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Regarding biodistribution, intravenous (I.V.) administration showed a slight advantage of FRα targeted over non-targeted micelleplex accumulation within the tumor.
|
29935386 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistent with this, FOLR1 expression in tumors progressing following cisplatin treatment was lower than levels in tumors in remission (P < 0.01).
|
29433550 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Folr1 targeted therapy attenuated the tumor growth and metastasis with down-regulation of MMPs proteins and activation of apoptosis.
|
28416738 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the protective model, in which C57BL/6 mice were immunized with the FRα DNA vaccine four weeks before tumor cell inoculation, the growth of tumor was significantly inhibited, and the presence of CpG ODN further increased the inhibitory effect.
|
28498413 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FRα expression in tumors was determined immunohistochemically.
|
28826214 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that PyMT-induced breast tumours highly express the cancer-specific folate receptor (FR), a feature they share with several human epithelial cancers in which expression of FRα correlates with tumour grade.
|
28152548 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Concordance of FRα expression in biopsy versus archival tumor samples suggests that archival tissue can reliably identify patients with receptor-positive tumors and is appropriate for patient selection in mirvetuximab soravtansine clinical trials.
|
28843653 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our work has demonstrated that localized delivery of FR-targeted PAMAM dendrimer G4 complexed with siVEGFA resulted in pronounced tumor suppression in an HN12 xenograft tumor model.
|
28438704 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although in primary EOC specimens, FRα is widely expressed and increases with tumor stage, PCFT was expressed independent of tumor stage (by real-time RT-PCR and IHC).
|
28138029 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Developing blastula and tumor cells both require folr1 expression to obtain folate.
|
28826993 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor targeting with folic acid radioconjugates has been proposed as a promising strategy for radionuclide therapy of folate receptor α (FR)-positive cancer.
|
28094532 |
2017 |